CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in government investments and R&D expenditure in pharmaceutical & biotechnology companies
3.5.1.2.Surge in usage of synthesized oligonucleotides in molecular diagnostics and clinical applications
3.5.1.3.Rise in demand for high end customized oligos and upgradation in purification
3.5.2.Restraints
3.5.2.1.Complexities associated with therapeutic oligos
3.5.2.2.Challenging delivery of oligonucleotide drugs to specific targets
3.5.3.Opportunities
3.5.3.1.Growth opportunities in emerging economies
3.5.3.2.Growing focus on personalized medicine
3.5.4.Impact analysis
3.6.COVID-19 impact analysis on the oligonucleotide synthesis market
CHAPTER 4: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Oligonucleotide-based drugs
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Synthesized oligonucleotides
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Reagents
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Equipment
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
CHAPTER 5: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Therapeutic applications
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by Product
5.3.Research applications
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by Product
5.4.Diagnostic applications
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.4.3.Market size and forecast, by Product
CHAPTER 6: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Pharmaceutical & biotechnology companies
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Diagnostic laboratories
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
6.5.CROs and CMOs
6.5.1.Market size and forecast
6.5.2.Market analysis, by country
6.6.Academic research institutes
6.6.1.Market size and forecast
6.6.2.Market analysis, by country
CHAPTER 7: OLIGONUCLEOTIDE SYNTHESIS, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. oligonucleotide synthesis market, by product
7.2.2.1.2.U.S. oligonucleotide synthesis market, by application
7.2.2.1.3.U.S. oligonucleotide synthesis market, by end user
7.2.2.2.Canada
7.2.2.2.1.Canada oligonucleotide synthesis, by product
7.2.2.2.2.Canada oligonucleotide synthesis market, by application
7.2.2.2.3.Canada oligonucleotide synthesis market, by end user
7.2.2.3.Mexico
7.2.2.3.1.Mexico oligonucleotide synthesis market, by product
7.2.2.3.2.Mexico oligonucleotide synthesis market, by application
7.2.2.3.3.Mexico oligonucleotide synthesis market, by end user
7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany oligonucleotide synthesis market, by product
7.3.2.1.2.Germany oligonucleotide synthesis market, by application
7.3.2.1.3.Germany oligonucleotide synthesis market, by end user
7.3.2.2.France
7.3.2.2.1.France oligonucleotide synthesis market, by product
7.3.2.2.2.France oligonucleotide synthesis market, by application
7.3.2.2.3.France oligonucleotide synthesis market, by end user
7.3.2.3.UK
7.3.2.3.1.UK oligonucleotide synthesis market, by product
7.3.2.3.2.UK oligonucleotide synthesis market, by application
7.3.2.3.3.UK oligonucleotide synthesis market, by end user
7.3.2.4.Italy
7.3.2.4.1.Italy oligonucleotide synthesis market, by product
7.3.2.4.2.Italy oligonucleotide synthesis market, by application
7.3.2.4.3.Italy oligonucleotide synthesis market, by end user
7.3.2.5.Spain
7.3.2.5.1.Spain oligonucleotide synthesis market, by product
7.3.2.5.2.Spain oligonucleotide synthesis market, by application
7.3.2.5.3.Spain oligonucleotide synthesis market, by end user
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe oligonucleotide synthesis market, by product
7.3.2.6.2.Rest of Europe oligonucleotide synthesis market, by application
7.3.2.6.3.Rest of Europe oligonucleotide synthesis market, by end user
7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan Oligonucleotide synthesis market, by product
7.4.2.1.2.Japan oligonucleotide synthesis market, by application
7.4.2.1.3.Japan oligonucleotide synthesis market, by end user
7.4.2.2.China
7.4.2.2.1.China Oligonucleotide synthesis market, by product
7.4.2.2.2.China oligonucleotide synthesis market, by application
7.4.2.2.3.China Oligonucleotide synthesis market, by end user
7.4.2.3.Australia
7.4.2.3.1.Australia oligonucleotide synthesis market, by product
7.4.2.3.2.Australia oligonucleotide synthesis market, by application
7.4.2.3.3.Australia oligonucleotide synthesis market, by end user
7.4.2.4.India
7.4.2.4.1.India oligonucleotide synthesis market, by product
7.4.2.4.2.India oligonucleotide synthesis market, by application
7.4.2.4.3.India oligonucleotide synthesis market, by end user
7.4.2.5.South Korea
7.4.2.5.1.South Korea oligonucleotide synthesis market, by product
7.4.2.5.2.South Korea oligonucleotide synthesis market, by application
7.4.2.5.3.South Korea Oligonucleotide synthesis market, by end user
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific oligonucleotide synthesis market, by product
7.4.2.6.2.Rest of Asia-Pacific oligonucleotide synthesis market, by application
7.4.2.6.3.Rest of Asia-Pacific oligonucleotide synthesis market, by end user
7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil oligonucleotide synthesis market, by product
7.5.2.1.2.Brazil oligonucleotide synthesis market, by application
7.5.2.1.3.Brazil oligonucleotide synthesis market, by end user
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia oligonucleotide synthesis market, by product
7.5.2.2.2.Saudi Arabia oligonucleotide synthesis market, by application
7.5.2.2.3.Saudi Arabia oligonucleotide synthesis market, by end user
7.5.2.3.South Africa
7.5.2.3.1.South Africa oligonucleotide synthesis market, by product
7.5.2.3.2.South Africa oligonucleotide synthesis market, by application
7.5.2.3.3.South Africa oligonucleotide synthesis market, by end user
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA oligonucleotide synthesis market, by product
7.5.2.4.2.Rest of LAMEA oligonucleotide synthesis market, by application
7.5.2.4.3.Rest of LAMEA oligonucleotide synthesis market, by end user
7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1.ALNYLAM PHARMACEUTICALS, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.BIOGEN LIMITED
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.CINVEN
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.4.DANAHER CORPORATION
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.EUROFINS SCIENTIFIC
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.IONIS PHARMACEUTICALS, INC.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.KANEKA CORPORATION
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.MERCK KGAA
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.SAREPTA THERAPEUTICS, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
